These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Risacher SL; Kim S; Shen L; Nho K; Foroud T; Green RC; Petersen RC; Jack CR; Aisen PS; Koeppe RA; Jagust WJ; Shaw LM; Trojanowski JQ; Weiner MW; Saykin AJ; Front Aging Neurosci; 2013; 5():11. PubMed ID: 23554593 [TBL] [Abstract][Full Text] [Related]
4. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau. Dickerson BC; Wolk DA; Front Aging Neurosci; 2013; 5():55. PubMed ID: 24130528 [TBL] [Abstract][Full Text] [Related]
5. The structural MRI markers and cognitive decline in prodromal Alzheimer's disease: a 2-year longitudinal study. Wei H; Kong M; Zhang C; Guan L; Ba M; Quant Imaging Med Surg; 2018 Nov; 8(10):1004-1019. PubMed ID: 30598878 [TBL] [Abstract][Full Text] [Related]
6. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease. Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800 [TBL] [Abstract][Full Text] [Related]
7. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid. Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990 [TBL] [Abstract][Full Text] [Related]
9. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601 [TBL] [Abstract][Full Text] [Related]
10. Sex modulates the ApoE ε4 effect on brain tau deposition measured by Liu M; Paranjpe MD; Zhou X; Duy PQ; Goyal MS; Benzinger TLS; Lu J; Wang R; Zhou Y Theranostics; 2019; 9(17):4959-4970. PubMed ID: 31410194 [TBL] [Abstract][Full Text] [Related]
11. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H; Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152 [TBL] [Abstract][Full Text] [Related]
12. A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and non-converter Alzheimer's disease subjects with consideration for their amyloid beta status. Morar U; Izquierdo W; Martin H; Forouzannezhad P; Zarafshan E; Unger E; Bursac Z; Cabrerizo M; Barreto A; Vaillancourt DE; DeKosky ST; Loewenstein D; Duara R; Adjouadi M Alzheimers Dement (Amst); 2022; 14(1):e12258. PubMed ID: 35229014 [TBL] [Abstract][Full Text] [Related]
13. The Effects of CSF Neurogranin and Fan Y; Gao Y; Therriault J; Luo J; Ba M; Zhang H; Front Aging Neurosci; 2021; 13():667899. PubMed ID: 33986657 [TBL] [Abstract][Full Text] [Related]
14. Neurogranin as a predictor of memory and executive function decline in MCI patients. Headley A; De Leon-Benedetti A; Dong C; Levin B; Loewenstein D; Camargo C; Rundek T; Zetterberg H; Blennow K; Wright CB; Sun X; Neurology; 2018 Mar; 90(10):e887-e895. PubMed ID: 29429972 [TBL] [Abstract][Full Text] [Related]
15. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study. Zhang H; Lyu D; Jia J; J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042 [TBL] [Abstract][Full Text] [Related]
16. Sex differences in the association between AD biomarkers and cognitive decline. Koran MEI; Wagener M; Hohman TJ; Brain Imaging Behav; 2017 Feb; 11(1):205-213. PubMed ID: 26843008 [TBL] [Abstract][Full Text] [Related]
17. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e. Susanto TA; Pua EP; Zhou J; J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955 [TBL] [Abstract][Full Text] [Related]
18. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database. Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A; J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972 [TBL] [Abstract][Full Text] [Related]
19. Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers. Jang H; Park J; Woo S; Kim S; Kim HJ; Na DL; Lockhart SN; Kim Y; Kim KW; Cho SH; Kim SJ; Seong JK; Seo SW; Neuroimage Clin; 2019; 24():101941. PubMed ID: 31376643 [TBL] [Abstract][Full Text] [Related]
20. The relationship between white matter microstructure and self-perceived cognitive decline. Archer DB; Moore EE; Pamidimukkala U; Shashikumar N; Pechman KR; Blennow K; Zetterberg H; Landman BA; Hohman TJ; Jefferson AL; Gifford KA Neuroimage Clin; 2021; 32():102794. PubMed ID: 34479171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]